Tecentriq 1 200 mg concentrate for solution for infusion clinical trials

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair (ATOMIC)

This study is looking at a new treatment for stage 3 bowel cancer that has a specific genetic feature. It compares standard chemotherapy with chemotherapy plus a new drug called atezolizumab (Tecentriq) to see if the new combination helps people live longer without their cancer coming back.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide with or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer

This study is looking into new ways to treat a serious type of lung cancer called small cell lung cancer. It combines standard chemotherapy with a new drug, tiragolumab, and an existing cancer drug, Tecentriq, to see if this mix works better than current treatments.

A PHASE 1/2 STUDY OF ONCOBAX®-AK ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPY TO PATIENTS WITH ADVANCED SOLID TUMORS

This study is testing a new treatment called Oncobax®-AK, given alongside established immunotherapy drugs, for people with advanced lung or kidney cancer. It's looking for the safest dose and early signs of how well it works. This is an early-stage trial, focusing on safety.

BARBICAN: A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer

This study looks at new treatments for a specific type of breast cancer called triple-negative. It combines standard chemotherapy and Tecentriq with a new drug, Ipatasertib, to see if this combination helps shrink tumours more effectively before surgery.

Phase Ib/II trial of the combination of atezolizumab with dendritic cell vaccination as maintenance treatment in patients with extensive stage small cell lung cancer (ES-SCLC) after induction treatment.

This study is looking at a new way to treat extensive small cell lung cancer. It combines a drug called atezolizumab with a special vaccine made from your own cells. The aim is to see if this combination can help people live longer without their cancer growing after initial treatment.

A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix (BEATcc )

This study is testing new treatments for advanced cervical cancer. It compares adding two medicines, Teccentriq and Avastin, to standard chemotherapy, against chemotherapy with just Avastin. Doctors want to see if this combination helps patients live longer and stops the cancer from growing.

Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer (AtezoLACC)

This study is testing a new medicine, Tecentriq, for women with locally advanced cervical cancer. We want to see if it helps patients live longer without their cancer getting worse, compared to standard treatments.

ALBAN : An open label, randomized, phase III trial, evaluating efficacy of Atezolizumab in addition to one year BCG (Bacillus CaLmette-Guerin) bladder instillation in BCG-naive patients with high-risk non-muscle invasive Bladder cANcer

This study looks at a new drug, Tecentriq, combined with standard BCG treatment for high-risk, early bladder cancer that hasn't spread to the muscle. It wants to see if this combination can stop the cancer from coming back or getting worse.

A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment

This study looks at a new combination treatment for advanced kidney cancer that has grown despite earlier immune-boosting treatment. Researchers want to see if combining two drugs, Atezolizumab and Cabozantinib, works better than Cabozantinib alone to control the cancer and help people live longer.

A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL

This study is testing a new combination of medicines (Venclexta, Tecentriq, and Gazyvaro) for adults with Richter Transformation, a type of aggressive cancer linked to chronic lymphocytic leukemia (CLL). Doctors want to see if this treatment is safe and helps shrink the cancer.

An open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).

This study looks at a new drug, GB1211, combined with an existing one, atezolizumab (Tecentriq), for non-small cell lung cancer. Researchers want to see if this combination is safe and how well it works to shrink tumours or stop them from growing. It involves different study parts.

A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after Targeted therapies

This study looks at a new combination of existing medicines for a type of lung cancer (NSCLC) that has worsened after previous treatments. It aims to see how many patients respond positively to this new treatment approach.

TEMPLE - Thiopurine Enhanced Mutations for PD-1/​Ligand-1 Efficacy

This study is testing new ways to treat cancer. It combines standard cancer drugs with newer immunotherapy to see if they work better together. Researchers are also looking for the best dose and how safe this new treatment is.

Programmed death ligand 1 (PD-L1) PET imaging in patients with (Diffuse) Large B-cell Lymphoma who are treated with CD19-directed CAR T-cell therapy: a pilot study

This study looks at a special scan before CAR T-cell therapy for lymphoma. It uses a tracer to see how certain proteins in lymphoma cells react. The aim is to understand how this scan can predict treatment success and help tell the difference between active lymphoma and normal swelling.

Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer (APTneo)

This study looks at new drug combinations for women with a certain type of aggressive breast cancer before surgery. It aims to see if these treatments can stop the cancer from coming back and improve long-term health, comparing their effects and safety.

Fecal Microbiota Transplant (FMT) combined with Atezolizumab plus Bevacizumab in Patients with HepatoCellular Carcinoma who failed to respond to prior Immunotherapy – the FAB-HCC pilot study

This study is looking at a new way to treat liver cancer (hepatocellular carcinoma) when previous immune treatments haven't worked. It combines two existing medicines, Avastin and Tecentriq, with something called Fecal Microbiota Transplant (FMT) to see if it helps patients and if it's safe.

DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.

This study looks at a new drug, obrixtamig, alongside usual treatment for extensive small cell lung cancer. It aims to see if this new combination helps people live longer and feel better compared to the usual treatment alone.

A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients With resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, an Anti- TIGIT Antibody, in Combination with Atezolizumab in Chemotherapy-Naive Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Clinical investigation evaluating safety and efficacy of selective intra-arterial 166Holmium radiation therapy in combination with atezolizumab and bevacizumab for non resectable Hepatocellular carcinoma (HOLMBRAVE)

An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined with Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia

A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in combination with Atezolizumab plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab plus Pemetrexed and Carboplatin/Cisplatin in Patients with previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients with Urothelial Carcinoma (MORPHEUS-UC)

OPTIMUNE-LUNG : INTEGRATIVE ANALYSIS OF THE TUMOR MICROENVIRONMENT AND OPTIMIZATION OF THE IMMUNOTHERAPY DURATION IN NON-SMALL CELL LUNG CANCER PATIENTS

A Phase II, Randomized, Double-Blind Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients with Recurrent/Metastatic PD-L1-Positive Squamous Cell Carcinoma of the Head and Neck

A phase II trial of Atezolizumab plus induction chemotherapy (CT) plus chemo-radiotherapy and Atezolizumab maintenance therapy in non-resectable stage IIIA-IIIB-IIIC non-small cell lung cancer (NSCLC) patients (APOLO)

A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer